K. Singh

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)

B. Matyjaszek-Matuszek, D. Kramer, My-Liên Nguyên-Pascal, 2022, Diabetes Therapy.

Ruptured pulmonary artery aneurysm: a surgical emergency

H. Kaur, T. S. Mahant, Rahat Brar, 2011, Asian cardiovascular & thoracic annals.

Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries

G. Fulcher, A. Kok, N. Nicodemus, 2022, Advances in Therapy.

Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy

Viswanathan Mohan, W. Schmider, K. P. Singh, 2022, Indian journal of endocrinology and metabolism.

Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries

G. Fulcher, A. Kok, N. Nicodemus, 2022, Advances in Therapy.

ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design

G. Fulcher, A. Kok, N. Nicodemus, 2021, Endocrine.